Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M253Revenue $M28.9Net Margin (%)-178.1Altman Z-Score-7.0
Enterprise Value $M126EPS $-0.6Operating Margin %-179.1Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-178.1Higher ROA y-yY
Price/Book2.810-y EBITDA Growth Rate %--Quick Ratio3.8Cash flow > EarningsY
Price/Sales8.55-y EBITDA Growth Rate %--Current Ratio3.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-34.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-48.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M90.6ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RIGL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RIGLJohn Paulson 2015-12-31 Buy 0.01%$2.53 - $3.55
($3.05)
$ 2.79-9%New holding528,700
RIGLCharles Brandes 2015-09-30 Reduce$2.36 - $3.35
($2.98)
$ 2.79-6%Reduce -44.07%25,000
RIGLCharles Brandes 2015-03-31 Buy $2.06 - $3.68
($2.74)
$ 2.792%New holding44,700
RIGLCharles Brandes 2014-09-30 Sold Out $1.97 - $3.84
($2.81)
$ 2.79-1%Sold Out0
RIGLCharles Brandes 2014-03-31 Buy $2.7 - $4.75
($3.53)
$ 2.79-21%New holding15,000
RIGLGeorge Soros 2011-12-31 Sold Out -0.0019%$6.68 - $8.3
($7.59)
$ 2.79-63%Sold Out0
RIGLFirst Eagle Investment 2011-06-30 Sold Out $7.11 - $9.19
($8.07)
$ 2.79-65%Sold Out0
RIGLGeorge Soros 2011-06-30 Buy $7.18 - $9.19
($8.08)
$ 2.79-65%New holding14,500
RIGLFirst Eagle Investment 2011-03-31 Buy $6.54 - $7.74
($7.06)
$ 2.79-60%New holding46,700
RIGLGeorge Soros 2010-09-30 Sold Out $6.94 - $8.8
($8.11)
$ 2.79-66%Sold Out0
RIGLGeorge Soros 2010-03-31 Add$7.41 - $9.83
($8.55)
$ 2.79-67%Add 34.29%14,100
RIGLGeorge Soros 2009-12-31 Buy $6.08 - $9.86
($7.86)
$ 2.79-65%New holding10,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RIGL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RIGL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PAYAN DONALD GEVP, Pres. Discovery&Research 2015-06-10Sell41,666$3.68-24.18view
PAYAN DONALD GEVP, Pres. Discovery&Research 2015-04-01Sell10,000$3.75-25.6view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2014-12-18Sell1,000$2.2225.68view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2014-12-18Sell1,000$2.2225.68view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-09-03Sell20,000$2.568.98view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-02-24Sell20,000$3.71-24.8view
BVF PARTNERS L P/IL10% Owner 2013-11-19Sell484,622$2.645.68view
BVF PARTNERS L P/IL10% Owner 2013-06-07Buy32,700$3.47-19.6view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2012-09-13Sell4,151$10.43-73.25view
Maynard Ryan DEVP & CFO 2012-09-12Sell23,302$10.67-73.85view

Quarterly/Annual Reports about RIGL:

News about RIGL:

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results Apr 26 2016
Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results Apr 26 2016
Rigel Pharma upgraded by JP Morgan Apr 22 2016
Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference Apr 12 2016
Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference Apr 12 2016
Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP Apr 01 2016
Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP Apr 01 2016
ETF’s with exposure to Rigel Pharmaceuticals, Inc. : March 15, 2016 Mar 15 2016
Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 14 2016
RIGEL PHARMACEUTICALS INC Financials Mar 12 2016
Edited Transcript of RIGL earnings conference call or presentation 8-Mar-16 10:00pm GMT Mar 09 2016
Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today Mar 08 2016
Rigel reports 4Q loss Mar 08 2016
Rigel reports 4Q loss Mar 08 2016
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 08 2016
Rigel Announces Fourth Quarter and Year End 2015 Financial Results Mar 08 2016
Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer Mar 08 2016
Q4 2015 Rigel Pharmaceuticals Inc Earnings Release - After Market Close Mar 08 2016
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial... Mar 01 2016
Rigel to Present at Cowen and Company 36th Annual Health Care Conference Feb 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)